Comparative Pharmacology
Head-to-head clinical analysis: DELATESTRYL versus ORA TESTRYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELATESTRYL versus ORA TESTRYL.
DELATESTRYL vs ORA-TESTRYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone ester; binds to androgen receptors, activating gene transcription and promoting protein synthesis, muscle growth, and secondary sexual characteristics.
Testosterone replacement therapy; binds to androgen receptors, promoting protein synthesis, muscle growth, and secondary sexual characteristic development.
50 to 200 mg intramuscularly every 2 to 4 weeks.
Intramuscular injection: 50-100 mg every 2-4 weeks.
None Documented
None Documented
8 days (terminal); requires 5-6 weeks to reach steady state with weekly dosing
Terminal half-life 2.5-3.5 hours; clinical context: requires multiple daily dosing to maintain steady-state levels
Urinary (90% as glucuronide and sulfate conjugates, 5% as unchanged drug); fecal (5%)
Renal (90% as glucuronide and sulfate conjugates, 10% unchanged); Biliary/fecal (10%)
Category C
Category C
Androgen
Androgen